241 related articles for article (PubMed ID: 21139495)
1. Imaging patients with kidney disease: how do we approach contrast-related toxicity?
Perazella MA; Reilly RF
Am J Med Sci; 2011 Mar; 341(3):215-21. PubMed ID: 21139495
[TBL] [Abstract][Full Text] [Related]
2. Gadolinium-Induced Fibrosis.
Todd DJ; Kay J
Annu Rev Med; 2016; 67():273-91. PubMed ID: 26768242
[TBL] [Abstract][Full Text] [Related]
3. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
[TBL] [Abstract][Full Text] [Related]
4. [Renal toxicity of contrast agents in oncologic patients].
Amet S; Deray G
Bull Cancer; 2012 Mar; 99(3):295-307. PubMed ID: 22082610
[TBL] [Abstract][Full Text] [Related]
5. [Artificial contrasting during magnetic resonance tomography].
Sergeev PV; Panov OV; Egorova SV; Bolotova EN; Shimanovskii NL; Akhadov TA; Sviridov NK
Vestn Rentgenol Radiol; 1997; (1):45-52. PubMed ID: 9133071
[No Abstract] [Full Text] [Related]
6. Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes.
Kane GC; Stanson AW; Kalnicka D; Rosenthal DW; Lee CU; Textor SC; Garovic VD
Nephrol Dial Transplant; 2008 Apr; 23(4):1233-40. PubMed ID: 18256017
[TBL] [Abstract][Full Text] [Related]
7. Renal Safety of Intravenous Gadolinium-enhanced MRI in Patients Following Liver Transplantation.
Flynn MM; Parekh AN; Parikh MR; Sood A; Shaffer KM; Runge TM; Lipowska AM; Perez SD; Sakaria SS; Subramanian RM
Transplantation; 2019 Jun; 103(6):e159-e163. PubMed ID: 30801544
[TBL] [Abstract][Full Text] [Related]
8. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
[TBL] [Abstract][Full Text] [Related]
9. Nephrogenic systemic fibrosis in Japan: advisability of keeping the administered dose as low as possible.
Tsushima Y; Takahashi-Taketomi A; Endo K
Radiology; 2008 Jun; 247(3):915-6. PubMed ID: 18487548
[No Abstract] [Full Text] [Related]
10. Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update.
Kanal E; Broome DR; Martin DR; Thomsen HS
Radiology; 2008 Jan; 246(1):11-4. PubMed ID: 17855656
[No Abstract] [Full Text] [Related]
11. [Risk-group patients due to the administration of iodine and gadolinium preparations for diagnostic clinical study].
Napolov IuK; Korobkova IZ; Maslennikov MA
Vestn Rentgenol Radiol; 2011; (1):29-40. PubMed ID: 21598470
[TBL] [Abstract][Full Text] [Related]
12. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.
Chrysochou C; Power A; Shurrab AE; Husain S; Moser S; Lay J; Salama AD; Kalra PA
Clin J Am Soc Nephrol; 2010 Mar; 5(3):484-9. PubMed ID: 20093350
[TBL] [Abstract][Full Text] [Related]
13. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
14. Type of MRI contrast, tissue gadolinium, and fibrosis.
Do C; Barnes JL; Tan C; Wagner B
Am J Physiol Renal Physiol; 2014 Oct; 307(7):F844-55. PubMed ID: 25100280
[TBL] [Abstract][Full Text] [Related]
15. Negligible Risk of Acute Renal Failure Among Hospitalized Patients After Contrast-Enhanced Imaging With Iodinated Versus Gadolinium-Based Agents.
Gorelik Y; Yaseen H; Heyman SN; Khamaisi M
Invest Radiol; 2019 May; 54(5):312-318. PubMed ID: 30480553
[TBL] [Abstract][Full Text] [Related]
16. [Anaphylactoid reaction caused by intravenous gadopentetate dimeglumine in magnetic resonance].
Campos A; Aznar L; Alamar R; Castelló JV
Med Clin (Barc); 1996 Feb; 106(5):197. PubMed ID: 8684023
[No Abstract] [Full Text] [Related]
17. Use of Gadolinium in Individuals with Reduced Kidney Function.
Kalantari K; Swaminathan S
Clin J Am Soc Nephrol; 2021 Feb; 16(2):304-306. PubMed ID: 33431379
[No Abstract] [Full Text] [Related]
18. Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice.
Meng H; Grosse-Wortmann L
J Cardiovasc Magn Reson; 2012 Aug; 14(1):56. PubMed ID: 22871150
[TBL] [Abstract][Full Text] [Related]
19. Can gadolinium be safely given in renal failure?
Weissleder R
AJR Am J Roentgenol; 1996 Jul; 167(1):278-9. PubMed ID: 8659405
[No Abstract] [Full Text] [Related]
20. The use of gadolinium for arterial interventions.
Sambol EB; Van der Meer JG; Graham A; Goldstein LJ; Karwowski JK; Dayal R; Derubertis B; Kent KC
Ann Vasc Surg; 2011 Apr; 25(3):366-76. PubMed ID: 21288688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
